N/A N=42 Performance of Toric Silicone Hydrogel Contact Lenses Following One Month of Daily Wear
Astigmatism
Primary: Lens Centration — 41; 1; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=47 Positive Psychology for Acute Coronary Syndrome Patients
ACS - Acute Coronary Syndrome
Primary: Feasibility of the PP-MI Based Health Behavior Intervention — 10.0 exercises completed
Phase 4 N=64 Perimenopausal Effects of Estradiol on Reward Responsiveness
Perimenopausal Depression
Primary: Caudate Signal Intensity in Response to Reward During the MID fMRI Task at Pre-treatment — .027; .043 percent signal change — p=.620
Phase 1 N=72 A Trial In Patients With Advanced Cancer And Leukemia
Neoplasms by Histologic Type
Primary: Number of Solid Tumor Participants With First-Cycle Dose-Limiting Toxicity (DLT) — 0; 0; 0; 1 participants
N/A N=147 Trial of Rifaximin in the Treatment of Tropical Enteropathy
Tropical Enteropathy
Primary: Difference in the Urinary L:M Ratio Before and After the Intervention — -0.01; 0.02 Ratio of lactulose-to-mannitol (L:M) exc
N/A N=40 Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia
Osteopenia · Bone Disease, Metabolic
Primary: Changes in Serum Level of Carboxyterminal Cross-linked Telopeptide of Type I Collagen (CTX); Over Time, i.e. Baseline, 3 Months, 6 Months. — 0.64; 0.64; 0.63; 0.56 µg/L…
N/A N=1,064 RESPOND Post Market Study
Aortic Valve Stenosis
Primary: All-cause Mortality — 26; 0 Participants — p=<.0001
Phase 1 N=77 A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)
Locally Advanced, Metastatic Solid Tumors
Primary: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 — 1; 2; 1; 1 Participants
N/A N=99 PainTracker Self-Manager: a Web-based Platform to Promote and Track Chronic Pain Self-management
Chronic Pain
Primary: Chronic Pain Self-efficacy — 27.33; 33.66; 28.39; 35.57 score on a scale — p=<0.05
Phase 2 N=51 Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer
Oligometastatic Non-small Cell Lung Cancer (NSCLC)
Primary: Progression Free Survival (PFS) — 19.1 Months
N/A N=197 Use of a Novel Computerized Decision Aid for Prenatal Aneuploidy Screening
Aneuploidy · Pregnancy Complications
Primary: Knowledge Score — 10.6; 10.2 score on a scale — p=0.929
Phase 2 N=59 Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease
Chronic Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 94.9; 92.0; 100.0; 93.8 percentage of participants
N/A N=2,062 Diabetes Prevention Using SMS Technology
Prediabetes
Primary: Number of Participants With Progression to Type 2 Diabetes — 216; 234 Participants
Phase 3 N=1,021 A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
Squamous Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat…
Phase 2 N=50 Resuscitative Endocrinology:Single-dose Clinical Uses for Estrogen-Traumatic Brain Injury
Traumatic Brain Injury
Primary: Percent Passing the Galveston Orientation Amnesia Test (GOAT) Within 28 Days Post Injury — 12; 14 Participants — p=0.99